Hughes, T., Cortés, J., Vaughn, J., Flynn, K., Takahashi, N., Issa, G., Bombaci, F., Wang, J., Kim, D., Kim, D., Mayer, J., Goh, Y. T., Coutre, P. L., Kim, I., Etienne, G., Jinwal, R., Damon, A., Wei, D., Marquez, G., Gu, E., Bommidi, G. M., Hochhaus, A., Larson, R. (2025). Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial. Blood. https://doi.org/10.1182/blood-2025-5549